holds several positive signals, but we still don't find these to be enough for a buy candidate. There is a buy signal from a pivot bottom found 11 days ago.) (This stock has medium daily movements and this gives medium risk. For the last week, the stock has had a daily average volatility of 8.68%. During the last day, the stock moved $1.22 between high and low, or 3.82%. This stock has average movements during the day and with good trading volume, the risk is considered to be medium. finds support from accumulated volume at $32.31 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested. A break-up through the long-term average will give another buy signal, while a fall below the short-term average will add another sell signal and strengthen the general signal. On a fall, the stock will find some support from the short-term average at $31.77. On further gains, the stock will meet resistance from the long-term moving average at $33.87. Since the longterm average is above the short-term average there is a general sell signal in the stock giving a more negative forecast for the stock.
stock holds a buy signal from the short-term moving average at the same time, however, the long-term average holds a general sell signal. Some negative signals were issued as well, and these may have some influence on the near short-term development. This causes a divergence between volume and price and it may be an early warning. Volume fell during the last trading day despite gaining prices. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Further rise is indicated until a new top pivot has been found. Thank you for reading.A buy signal was issued from a pivot bottom point on Monday, December 06, 2021, and so far it has risen 12.07%. Simply Wall St has no position in any stocks mentioned. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. We aim to bring you long-term focused analysis driven by fundamental data. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Alternatively, email article by Simply Wall St is general in nature.
Love or hate this article? Concerned about the content? Get in touch with us directly.
#RAPT THERAPEUTICS STOCK FREE#
So you may also wish to search this free list of stocks that insiders are buying. Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are downgrading their estimates.
#RAPT THERAPEUTICS STOCK FOR FREE#
Unsatisfied? At least one of RAPT Therapeutics' five analysts has provided estimates out to 2024, which can be seen for free on our platform here. Given the stark change in sentiment, we'd understand if investors became more cautious on RAPT Therapeutics after today. The clear low-light was that analysts slashing their revenue forecasts for RAPT Therapeutics this year. NasdaqGM:RAPT Past and Future Earnings June 4th 2020 The Bottom Line See our latest analysis for RAPT Therapeutics The consensus view seems to have become more pessimistic on RAPT Therapeutics, noting the measurable cut to revenue estimates in this update. Prior to the latest estimates, the analysts were forecasting revenues of US$3.3m in 2020. With such a sharp increase, it seems brokers may have seen something that is not yet being priced in by the wider market.įollowing the downgrade, the current consensus from RAPT Therapeutics' five analysts is for revenues of US$2.9m in 2020 which - if met - would reflect a major 213% increase on its sales over the past 12 months. Investors however, have been notably more optimistic about RAPT Therapeutics recently, with the stock price up a noteworthy 14% to US$20.43 in the past week. This report focused on revenue estimates, and it looks as though the consensus view of the business has become substantially more conservative. ( NASDAQ:RAPT), with the analysts making across-the-board cuts to their statutory estimates that might leave shareholders a little shell-shocked. The latest analyst coverage could presage a bad day for RAPT Therapeutics, Inc.
0 kommentar(er)
